ECONSALUT

Critical comments on health economics and policy

29 de juliol 2022

Against patents, again (3)

›
 Patent Politics. Life Forms, Markets, and the Public Interest in the United States and Europe Comparing battles over patents on animals, hu...
28 de juliol 2022

Against patents (2)

›
 Medical Monopoly. Intellectual Property Rights and the Origins of the Modern Pharmaceutical Industry Medical Monopoly combines legal, medic...
25 de juliol 2022

On epigenetics and health (2)

›
 The Epigenetics Revolution. How Modern Biology Is Rewriting Our Understanding of Genetics, Disease, and Inheritance The ‘epi’ in epigenetic...
20 de juliol 2022

Covid-19 response

›
 Covid-19. La respuesta autoritaria y la estrategia del miedo
14 de juliol 2022

Pharma, big pharma (14)

›
 Global Pharmaceutical Policy
13 de juliol 2022

Pharma, big pharma (13)

›
 Studies on Competition and Antitrust Issues in the Pharmaceutical Industry
12 de juliol 2022

Pharma, big pharma (12)

›
 Antitrust in Pharmaceutical Markets & Geographical Rules of Origin
11 de juliol 2022

Pharma, big pharma (11)

›
EU Law of Competition and Trade in the Pharmaceutical Sector 
10 de juliol 2022

Facing Covid-19

›
 The Courage to Face COVID-19: Preventing Hospitalization and Death While Battling the Bio-Pharmaceutical Complex
09 de juliol 2022

Obamacare revisited

›
 Crossing the American Health Care Chasm. Finding the Path to Bipartisan Collaboration in National Health Care Policy
08 de juliol 2022

Environmental impact on population health

›
 Environmental Policy and Public Health. Principal Health Hazards and Mitigation
07 de juliol 2022

Amartya Sen legacy

›
 Home in the World: A Memoir
06 de juliol 2022

AI everywhere (16)

›
 Machines Behaving Badly: The Morality of AI
05 de juliol 2022

What are the keys to human progress?

›
 The Journey of Humanity: The Origins of Wealth and Inequality
‹
›
Inici
Visualitza la versió per a web
Pere Ibern
Visualitza el meu perfil complet
Amb la tecnologia de Blogger.